2017 Fiscal Year Final Research Report
Mutational status in combined hepatocellular-cholangiocarcinoma
| Project/Area Number |
16K19096
|
|---|
| Research Category |
Grant-in-Aid for Young Scientists (B)
|
| Allocation Type | Multi-year Fund |
|---|
| Research Field |
Human pathology
|
|---|
| Research Institution | Kurume University |
|---|
Principal Investigator |
|
|---|
| Research Collaborator |
YANO Hirohisa 久留米大学, 医学部, 教授
AKIBA Jun 久留米大学病院, 病院病理部, 教授
OGASAWARA Sachiko 久留米大学, 医学部, 講師
NAITO Yoshiki 久留米大学病院, 病院病理部, 講師
KONDO Reiichiro 久留米大学, 医学部, 助教
NAKASHIMA Osamu 久留米大学病院, 臨床検査部, 教授
KAGE Masayoshi 久留米大学, 医学部, 客員教授
|
|---|
| Project Period (FY) |
2016-04-01 – 2018-03-31
|
| Keywords | 混合型肝癌 / 遺伝子異常 |
|---|
| Outline of Final Research Achievements |
Combined hepatocellular cholangiocarcinomas (CHCs) are divided into classical type (CHC-classical) and subtypes with stem-cell features. The latter is further classified into typical subtype (CHC-SC-typical), intermediate-cell subtype (CHC-SC-int), and cholangiolocellular subtype (CHC-SC-CLC) in the recent WHO classification. In this study, we analyzed a series of CHCs to clarify the clinicopathologic features and KRAS and IDH1/2 mutational status of each subtype. Compared with other CHCs, CHCs-SC-CLC were less frequently associated with chronic viral hepatitis, showed lower levels of serum AFP and DCP, and had higher frequency of IDH1/2 mutations. Compared with intrahepatic cholangiocarcinomas, CHCs-SC-CLC showed lower incidence of vascular invasion and nodal metastasis, lower level of serum CA19-9 and lower frequency of expression of S100P. Our results suggest that CHC-SC-CLC may be a distinct entity among primary liver carcinomas.
|
| Free Research Field |
人体病理学
|
